Diagnostic Imaging Can Rule Out CAD in Low-Risk Patients
The study was carried out by a research team from Medical Center Alkmaar (Alkmaar, The Netherlands) led by Friso van der Zant, MD, PhD. The team reviewed and analysed results of CCTA — a well-established, sensitive method of visualising non-obstructive CAD — and calcium scoring to determine the presence of non-calcified plaques in the coronary arteries, amongst women over an 18-month period.
Based on the results, the researchers concluded that the ability to exclude a diagnosis of CAD in about half of patients, while exposing them to only a modest dose of radiation, can have a substantial impact on patient management.
"In the present study, CCTA excluded CAD in 51 percent of the studied cohort and led to changes in patient management in 53 percent," Dr. van der Zant and co-authors write in the journal report. The effective dose from CCTA combined with calcium scoring was substantially lower than 10 mSv in the current study.
The lifetime risk of developing fatal cancer from radiation received from medical imaging examinations with an effective dose of 10 mSv, the researchers note, is estimated to be 1 in 2000, which is >10-fold lower than the lifetime risk of dying in a motor vehicle accident (1 in 108 in the U.S.) and also lower than dying in a pedestrian accident (1 in 749).
Susan G. Kornstein, MD, Editor-in-Chief of Journal of Women's Health, Executive Director of the Virginia Commonwealth University Institute for Women's Health, Richmond, VA, and President of the Academy of Women's Health, comments on Dr. van der Zant's findings: "This study suggests that CCTA combined with calcium scoring is a useful diagnostic tool for excluding coronary artery disease in women with atypical chest pain, with minimal concerns about radiation exposure."
Source: Journal of Women's Health
Image credit: Wikimedia Commons
«« MBI: Cost-Effective Secondary Breast Screening Method
Collective Intelligence Improves Mammography Screening »»
Published on : Mon, 17 Aug 2015
3Dimensions™ Mammography System
A better 3D™ breast screening experience – for everyone. The new 3Dimensions™ system is designed to provide higher quality 3D™ images for radiologists, a more comfortable mammography experience for patients and enhanced workflow for technologists....
BioZorb® 3D Bioabsorbable Marker
BioZorb® 3D Bioabsorbable Marker The BioZorb® is a 3D implantable marker that consists of a spiral, bioabsorbable framework embedded with 6 permanent, titanium clips designed to precisely mark your surgical excision site. Designed to improve outcomes...
Breast Stabilization System
Transform the breast imaging patient experience The SmartCurve system provides a curved compression surface that offers a more comfortable patient experience without compromising image quality, exam time, dose or workflow.1 The SmartCurve system is...
Affirm® Breast Biopsy Guidance System
About the Affirm® breast biopsy guidance system Our passion to offer innovative interventional tools that advance breast health fueled the development of the Affirm breast biopsy guidance system. This simple add-on to any Hologic 3D Mammography™-capable...
Trident® Specimen Radiography System
Remarkable image quality, right at the point of care. The Trident system revolutionizes breast tissue imaging by incorporating a micro-focused tube, unique specimen image processing algorithms and amorphous selenium direct digital detector. The...